YOKNEAM, ISRAEL -- (Marketwire) -- 06/04/09 -- Syneron Medical Ltd. (NASDAQ: ELOS), an
innovator in the development, marketing and sales of elos(TM)
combined-energy medical aesthetic devices, announced today that Syneron
will participate in the Gabelli & Company Small Cap Healthcare Conference
on Tuesday, June 9, 2009 and in the Needham Growth Conference on Wednesday,
June 10, 2009, both in New York. Syneron CEO, Lou Scafuri, will present on
behalf of Syneron at 9:30am ET in the Gabelli & Company Small Cap
Healthcare Conference and at 8:00am ET in the Needham Growth Conference.
The presentations will be web cast live over the Internet and can be
accessed through the 'Investor Overview' page on the Syneron's website at
www.syneron.com. Please go to the website a few minutes early, as it may be
necessary to download audio software to hear the presentations.
About Syneron
Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes medical
aesthetic devices that are powered by the proprietary, patented elos
combined-energy technology of Bi-Polar Radio Frequency and Light. The
Company's innovative elos technology provides the foundation for highly
effective, safe and cost-effective systems that enable physicians to
provide advanced solutions for a broad range of medical-aesthetic
applications in the areas of facial applications, including skin
rejuvenation, wrinkle reduction, and skin tightening, and body shaping,
where the Company maintains a leadership position with its powerful
VelaShape(TM) platform for circumferential reduction and cellulite
treatment, and LipoLite(TM), Syneron's first device in the market for
laser-assisted lipolysis. Founded in 2000, the corporate, R&D, and
manufacturing headquarters for Syneron Medical Ltd. is located in Israel.
Syneron has offices and distributors throughout the world, including North
American Headquarters in Canada, North American Logistics Support Center in
Irvine, CA, European Headquarters in Germany, and Asia-Pacific Headquarters
in Hong Kong, which provide sales, service and support. Additional
information can be found at www.syneron.com.
Syneron, the Syneron logo, and elos are trademarks of Syneron Medical Ltd.
and may be registered in certain jurisdictions. Elos (Electro-Optical
Synergy) is a proprietary technology of Syneron Medical. All other names
are the property of their respective owners.
For more information, please contact:
Judith Kleinman
VP Investor Relations
+972 (54) 646-1688
email: Email Contact